Muzsnai A, Sólyom J, Ilyés I, Kovács J, Sólyom E, Niederland T, Péter F
Buda Childrens Hospital, Budapest, Hungary.
Horm Res. 2007;68 Suppl 5:205-6. doi: 10.1159/000110675. Epub 2007 Dec 10.
The Pfizer International Metabolic Database (KIMS), a large pharmacoepidemiologic database for adults with growth hormone deficiency (GHD), was recently analyzed to determine which tests are in use to assess GHD and how well they correlate. At the time of this analysis, a total of 15,724 tests had been reported to KIMS. The most frequently used is the insulin tolerance test (ITT), followed in order by the arginine stimulation test (AST), the glucagon stimulation test (GST) and the GH-releasing hormone+arginine (GHRH+arg) test. The ITT correlated with both the AST and the GST, but not with the GHRH+arg.
For the AST and GST, use of a diagnostic threshold of 3 mug/l does not attenuate the effects of severe GHD.
辉瑞国际代谢数据库(KIMS)是一个针对成人生长激素缺乏症(GHD)的大型药物流行病学数据库,最近进行了分析,以确定用于评估GHD的测试方法以及它们之间的相关性。在此次分析时,共有15724项测试报告至KIMS。最常用的是胰岛素耐量试验(ITT),其次依次是精氨酸刺激试验(AST)、胰高血糖素刺激试验(GST)和生长激素释放激素+精氨酸(GHRH+arg)试验。ITT与AST和GST均相关,但与GHRH+arg不相关。
对于AST和GST,使用3μg/L的诊断阈值不会减弱严重GHD的影响。